Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

Pfizer (PFE) closed the most recent trading day at $26.50, moving +2.4% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. At the same time, ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

SHANGHAI, CHINA - 2025/11/08: The Pfizer logo is presented at the 8th China International Import Expo. (Photo by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) Pfizer (PFE) is encountering ...

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year. Even if ...

Pfizer PFE stock has been trading above its 50-day moving average since early November, indicating a potential short-term bullish trend. The 50-day SMA is a key indicator for traders and analysts, ...

Pfizer's oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market. It might take a while longer, but Pfizer is on the path to ...